PALYNZIQ

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Japan, Lithuania, Poland.

Active ingredients

The drug PALYNZIQ contains one active pharmaceutical ingredient (API):

1	Pegvaliase UNII N6UAH27EUV - PEGVALIASE
	Pegvaliase is a PEGylated recombinant phenylalanine ammonia lyase enzyme that converts phenylalanine to ammonia and trans-cinnamic acid that are primarily eliminated by liver metabolism.
	Read more about Pegvaliase

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
PALYNZIQ Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)
PALYNZIQ Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A16AB19		A Alimentary tract and metabolism → A16 Other alimentary tract and metabolism products → A16A Other alimentary tract and metabolism products → A16AB Enzymes
Discover more medicines within A16AB19

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1795989, 1795990, 1796003, 1796070
FR	Base de données publique des médicaments	61661596, 65887105, 67940880
IT	Agenzia del Farmaco	047940010, 047940022, 047940034, 047940046
JP	医薬品医療機器総合機構	39994E9G1029, 39994E9G2025, 39994E9G3021
LT	Valstybinė vaistų kontrolės tarnyba	1087709, 1087710, 1087711, 1087712
PL	Rejestru Produktów Leczniczych	100421218, 100421224, 100421230
US	FDA, National Drug Code	68135-058, 68135-673, 68135-756